SGLT2 Inhibition in Older Obese Adults With Pre-diabetes
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
Inhibitors of the sodium-glucose co-transporter (SGLT2) are FDA-approved for the treatment of
type 2 diabetes (T2DM). Their mechanism of action involves lowering of blood glucose
concentration secondary to increased glucose excretion of glucose by the kidney. These drugs
also improve body weight, blood pressure, and cardiac function. Based on these pleiotropic
effects, including its calorie restriction-mimetic properties, the study team hypothesize
that SGLT2 drugs will impact several basic aging-related processes, including reductions in
oxidative damage to DNA and proteins, advanced glycation end products (AGE) and receptor for
AGE (RAGE), cellular senescence, and mitochondrial function.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The University of Texas Health Science Center at San Antonio